Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Sponsor
Ain Shams University
Study ID
NCT06901609
Status
Active Not Recruiting

Conditions

  • Cardiac Fibrosis
  • Cardiac Remodeling
  • Heart Failure - NYHA II - IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with HFrEF. Pharmacogenetics, the study of how genetic variations influence drug response, could elucidate inter-individual variability in treatment outcomes. This study aims to assess the impact of specific genetic variants on renal outcomes in HFrEF patients treated with SGLT2 inhibitors.

Key Dates

Start date
Nov 22, 2023
Status verified
Mar 2025
Primary completion
Jun 1, 2025
Completion
Jul 1, 2025

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Cohort A
    Newly diagnosed Heart Failure patients with reduced ejection fraction who are candidate for add-on treatment with sodium glucose transporter 2 inhibitor (SGLT2i) for the first time in addition to standard heart failure therapy.

Primary Outcome Measure

Reno-protective effect and gene polymorphism [ Time Frame: 6 months ]

Related Studies